Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer

BJU International

Volumn 92, Issue 1, 2003, Pages 24-27

  Sung, J ^a   Espiritu, J I ^b   Segall, G M ^b   Terris, M K ^a,c  

^a Section of Urology   (United States)

^b Nuclear Medicine Service   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Imaging; PET; Prostatic neoplasms; Staging; Tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT OUTCOME;

ABDOMINAL NEOPLASMS; AGED; BONE NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PELVIC NEOPLASMS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037826013     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04297.x     Document Type: Article

References (22)

1. Okada J, Yoshikaqu K, Imazeki K et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991; 32: 686-91
2. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998; 227: 746-9
3. Lucas JD, O'Doherty MJ, Wong JC et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br 1998; 80: 441-7
4. Saunders CA, Dussek JE, O'Doherty MD, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999; 67: 790-7
5. Ogunbiyi OA, Flanagan FL, Dehdashti F et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997; 4: 613-20
6. Fischbein NJ, Aassar OS, Caputo GR et al. Clinical utility of positron emission tomography with 19F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. Am J Neuroradiol 1998; 19: 1189-96
7. Tuzel E, Sevinc M, Obuz F, Sade M, Kirkali Z. Is magnetic resonance imaging necessary in the staging of prostate cancer? Urologia Intis 1998; 61: 227-31
8. Barbieri A, Monica B, Sebastio N, Incarbone GP, Di Stefano C. Value and limitations of transrectal ultrasonography and computer tomography in preoperative staging of prostate carcinoma. Acta Bio-Med L Ateneo Parmense 1997; 68: 23-6
9. Hoh CK, Seltzer MA, Franklin J et al. Positron emission tomography in urological oncology. J Urol 1998; 159: 347-56
10. Bender H, Schomburg A, Albers P, Ruhlmann J, Biersack HJ. Possible role of FDG-PET in the evaluation of urologic malignancies. Anticancer Res 1997; 17: 1655-60
11. Liu IJ, Segall GM, Nino-Murcia M, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of prostate cancer. Urology 2001; 57: 108-11
12. Hwang, DR, Lang, LX, Mathias, CJ, Kadmon, D, Welch, MJ N-3-[18F]fluoropropylputrescine as potential PET imaging agent for prostate and prostate derived tumors. J Nucl Medical 1989; 30: 1205-10
13. Hwang DR, Mathias CJ, Welch MJ, McGuire AH, Kadmon D. Imaging prostate derived tumors with PET and N-(3-[18F]fluoropropyl) putrescine. Int J Rad Appl Instrum 1990; 17: 525-32
14. Inaba T. Quantitative measurements of prostatic blood flow and blood Volume by positron emission tomography. J Urol 1992; 148: 1457-60
15. Bares R, Effert P, Handt S, Hanbenchen U. Positron-emission-tomography (PET) with fluorine-18 labeled deoxyglucose (FDG) in prostate cancer (PC): first results. J Nucl Med 1993; 34: 217P (A1021)
16. Effert PJ, Bares R, Handt S et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 1996; 155: 994-8
17. Oyama N, Akino H, Suzuki Y et al. The increased accumulation of [18F] fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 1999; 29: 623-9
18. Kao CH, Hsieh JF, Tsai SC, Ho YJ, Yen RF. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 2000; 20: 2189-92
19. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer. initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996; 199: 751-6
20. Heicappell R, Muller-Mattheis V, Reinhardt M et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18) F]-2-deoxy-D-glucose. Eur Urol 1999; 36: 582-7
21. Sanz G, Robles JE, Gimenez M et al. Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 1999; 84: 1028-31
22. Seltzer MA, Barbaric Z, Belldegrun A et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999; 162: 1322-8